Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.71 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | NAT1 | P18440 | 5/20 | 0.64 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.64 |
| ▸ | MYC | P01106 | 2/20 | 0.64 |
| ▸ | MAX | P61244 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | IDH1 | O75874 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250831 | 1.00 | CRHBP (0.71) | CRHBPCRHR2TDP1GSK3BNAT1 | |
| SCHEMBL15091291 | 1.00 | CRHBP (0.71) | CRHBPCRHR2TDP1GSK3BNAT1 | |
| SCHEMBL4834139 | 0.88 | TDP1 (0.75) | TDP1GSK3BCISD1MAOARAB9A | |
| SCHEMBL1249111 | 0.88 | TDP1 (0.75) | TDP1GSK3BCISD1MAOARAB9A | |
| SCHEMBL1249114 | 0.88 | TDP1 (0.75) | TDP1GSK3BCISD1MAOARAB9A | |
| SCHEMBL13846511 | 0.85 | NAT1 (0.68) | CRHBPCRHR2NAT1CISD1MYC | |
| SCHEMBL8309015 | 0.83 | CRHBP (1.00) | CRHBPCRHR2GSK3BNAT1CISD1 | |
| SCHEMBL8309014 | 0.83 | CRHBP (1.00) | CRHBPCRHR2GSK3BNAT1CISD1 | |
| SCHEMBL17183508 | 0.82 | MAPT (0.84) | CRHBPCRHR2GSK3BIDH1NPC1 | |
| SCHEMBL2184424 | 0.82 | MAPT (0.84) | CRHBPCRHR2GSK3BIDH1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016077793-A1 | SOS1 INHIBITORS FOR CANCER TREATMENT | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-2648046-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130177844-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| WO-2006082245-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
| EP-0506876-A4 | SUPER-HIGH CONTRAST SILVER HALIDE MATERIAL | INT PAPER CO (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0506876-A1 | SUPER-HIGH CONTRAST SILVER HALIDE MATERIAL | INTERNATIONAL PAPER COMPANY (US) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009345-A1 | SUPER-HIGH CONTRAST SILVER HALIDE MATERIAL | INTERNATIONAL PAPER COMPANY (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | CRHBP 124/4885CRHR2 1576/4885TDP1 4817/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | CRHBP 123/4885CRHR2 2192/4885TDP1 4829/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | CRHBP 77/4885CRHR2 1483/4885TDP1 4813/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | CRHBP 133/4885CRHR2 1651/4885TDP1 4842/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | CRHBP 121/4885CRHR2 2442/4885TDP1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.